ACTION FOR A-T — grant history
Latest income
£905k
Grants listed (FY2024)
10
Listed grants total
£1.6m
Accounts grants total
£1.5m
listed grants reconcile with the accounts totalextracted from its FY2024 accounts
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Leiden University Medical Centre, Netherlands | FY2024 | £250k | Functional impact of Nicotinamide Riboside on the immune system of patients with A-T |
| University of Kent, UK | FY2024 | £250k | Investigating the role of mutant Triple T chaperone in ATM assembly in Ataxia Telangiectasia |
| University of Hamburg and University of Birmingham | FY2024 | £250k | Development of suppressor tRNA-based therapeutics |
| University of Birmingham, UK | FY2024 | £249k | Identifying existing drugs to repurpose for treating Ataxia-Telangiectasia |
| University of North Carolina at Chapel Hill, USA | FY2024 | £249k | Development of a Gene Therapy approach to treat A-T |
| University of Nottingham, UK | FY2024 | £247k | Biomarkers for Babies and Young Children with Ataxia Telangiectasia (BOBCAT) |
| University College London (UCL), UK | FY2024 | £25k | Exploring Omaveloxolone efficacy in Ataxia-telangiectasia |
| University of Nottingham | FY2024 | £20k | Exploring the Use of Assistive Robots, Smart Sensing and Digital Twin Models for Monitoring and Support of Ataxia in Non-Clinical Environments |
| University of Cambridge | FY2024 | £20k | Improving diagnosis and treatment of cancer in Ataxia-Telangiectasia patients through whole genome sequencing |
| University of Nottingham | FY2024 | £19k | Kicking Kinases into Action: A novel drug screening assay for A-T |
| Institute for Bioengineering of Catalonia, Spain | FY2023 | £25k | Modelling Ataxia Telangiectasia pathogenesis and therapeutics using human pluripotent stem cells and genetic engineering |
| Oslo University Hospital, Norway | FY2023 | £25k | Preclinical Assessment of Intrathecal rAAV9-Mediated miATM Therapy for Ataxia Telangiectasia in Mouse Models |
| University of Nottingham, UK | FY2023 | £20k | STIM A-T Pilot Study |
| University of Nottingham, UK | FY2023 | £19k | Virtual Reality in Ataxia-Telangiectasia |
| University of Nottingham, UK | FY2023 | £863 | Sandpit Event |
| University of Birmingham, UK | FY2023 | £-29 | Deciphering the molecular mechanism linking Ataxia-Telangiectasia and Ataxia-Telangiectasia-Like Disorder (underspends refunded) |
| University of Birmingham, UK | FY2023 | £-15k | Assessment of the frequencies and types of cancers occurring in A-T patients (underspends refunded) |
| Nottingham University Hospital, UK | FY2023 | £-22k | Natural History of A-T (underspends refunded) |
| University of Cambridge, UK | FY2022 | £250k | Trial REadiness in Ataxia Telangiectasia (TREAT-AT) |
| QIMR Berghofer Medical Research Institute, Queensland, Australia | FY2022 | £152k | Digital drug prediction informed by genetic analysis of stem cell-derived mini-brains from A-T patients |
| University of Nottingham, UK | FY2022 | £147k | Brain-penetrating ATM gene therapy |
| IFOM – The FIRC Institute of Molecular Oncology, Milan, Italy | FY2022 | £126k | Understanding and correcting glucose metabolism defects in Ataxia-Telangiectasia |
| Bambino Gesù Children’s Hospital, Italy | FY2022 | £91k | Study of natural killer cells in A-T pathogenesis and their therapeutic implications |
| Nottingham University Hospital, UK | FY2022 | £-22k | (Research project underspends refunded) Natural History of A-T |